A canine case of malignant melanoma carrying a KIT c.1725_1733del mutation treated with toceranib: a case report and in vitro analysis

BMC Veterinary Research

Syunya Noguchi¹  Ryo Miyamoto²  Sena Kurita²  Kyoichi Tamura²  Hiroyuki Tani²  Makoto Bonkobara³  Masaki Michishita⁴  Tomokazu Nagashima⁵  Naoko Yayoshi⁶ 

[1] Department of Veterinary Anatomy, Nippon Veterinary and Life Science University, Tokyo, Japan;Department of Veterinary Clinical Pathology, Nippon Veterinary and Life Science University, Tokyo, Japan;Department of Veterinary Clinical Pathology, Nippon Veterinary and Life Science University, Tokyo, Japan;Research Center for Animal Life Science, Nippon Veterinary and Life Science University, Tokyo, Japan;Department of Veterinary Pathology, Nippon Veterinary and Life Science University, Tokyo, Japan;Research Center for Animal Life Science, Nippon Veterinary and Life Science University, Tokyo, Japan;Department of Veterinary Pathology, Nippon Veterinary and Life Science University, Tokyo, Japan;Veterinary Medical Teaching Hospital, Nippon Veterinary and Life Science University, Tokyo, Japan;Veterinary Medical Teaching Hospital, Nippon Veterinary and Life Science University, Tokyo, Japan;

关键词: Dog;    KIT;    Toceranib;    Malignant melanoma;    Mutation;   

DOI  :  10.1186/s12917-021-02864-3

来源: Springer

【 摘 要 】

BackgroundCanine malignant melanoma is highly aggressive and generally chemoresistant. Toceranib is a kinase inhibitor drug that inhibits several tyrosine kinases including the proto-oncogene receptor tyrosine kinase KIT. Although canine malignant melanoma cells often express KIT, a therapeutic effect for toceranib has yet to be reported for this tumor, with only a small number of patients studied to date. This is a case report of a dog with malignant melanoma that experienced a transient response to toceranib. Furthermore, the KIT expressed in the tumor of this case was examined using molecular analysis.Case presentationA Shiba Inu dog presented with a gingival malignant melanoma extending into surrounding structures with metastasis to a submandibular lymph node. The dog was treated with toceranib (Palladia®; 2.6–2.9 mg/kg, orally, every other day) alone. Improvement of tumor-associated clinical signs (e.g., halitosis, tumor hemorrhage, trismus, and facial edema) with reduced size of the metastatic lymph node was observed on Day 15. The gingival tumor and associated masses in the masseter and pterygoid muscles decreased in size by Day 29 of treatment. Toceranib treatment was terminated on Day 43 due to disease progression and the dog died on Day 54. The tumor of this dog had a novel deletion mutation c.1725_1733del within KIT and the mutation caused ligand-independent phosphorylation of KIT, which was suppressed by toceranib. This mutation was considered to be an oncogenic driver mutation in the tumor of this dog, thereby explaining the anti-tumor activity of toceranib.ConclusionsThis is the first report that presents a canine case of malignant melanoma that responded to toceranib therapy. KIT encoded by KIT harboring a mutation c.1725_1733del is a potential therapeutic target for toceranib in canine malignant melanoma. Further investigation of the KIT mutation status and toceranib therapy in canine malignant melanoma will need to be undertaken.

【 授权许可】

CC BY